saxagliptin · SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE 5 mg/1 · Tablet, Film Coated · Oral · Mylan Pharmaceuticals Inc.
NDC 00378-4706-93 · 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has fallen 79% in a year, to $1.05 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aurobindo Pharma Limited | SAXAGLIPTIN HYDROCHLORIDE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | SAXAGLIPTIN HYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | SAXAGLIPTIN HYDROCHLORIDE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | SAXAGLIPTIN HYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Saxagliptin — NDC 00378-4706-93," retrieved September 3, 2026, https://drugdashboards.com/drug/00378470693.
Free to cite with attribution — see how the data is put together.